UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
20.46
+0.85 (4.33%)
At close: Mar 6, 2026, 4:00 PM EST
20.58
+0.12 (0.59%)
After-hours: Mar 6, 2026, 6:25 PM EST
UroGen Pharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for UroGen Pharma stock have an average target of 29.29, with a low estimate of 3.00 and a high estimate of 47. The average target predicts an increase of 43.16% from the current stock price of 20.46.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +61.29% | Mar 2, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +61.29% | Jan 23, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +61.29% | Jan 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +95.50% | Oct 27, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +22.19% | Oct 27, 2025 |
Financial Forecast
Revenue This Year
240.84M
from 109.79M
Increased by 119.37%
Revenue Next Year
396.88M
from 240.84M
Increased by 64.79%
EPS This Year
-1.20
from -3.19
EPS Next Year
0.77
from -1.20
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 298.2M | 601.2M | |||
| Avg | 240.8M | 396.9M | |||
| Low | 187.3M | 294.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 171.6% | 149.6% | |||
| Avg | 119.4% | 64.8% | |||
| Low | 70.6% | 22.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.57 | 1.65 | |||
| Avg | -1.20 | 0.77 | |||
| Low | -1.67 | -0.17 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.